HIV Drug to Aid Melanoma Therapies?

Hyungsoo Kim; Ze'ev A Ronai

doi:10.1016/j.ccell.2016.02.014

HIV Drug to Aid Melanoma Therapies?

Cancer Cell. 2016 Mar 14;29(3):245-246. doi: 10.1016/j.ccell.2016.02.014.

Authors

Hyungsoo Kim¹, Ze'ev A Ronai²

Affiliations

¹ Tumor Initiation and Maintenance Program, Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
² Tumor Initiation and Maintenance Program, Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA. Electronic address: zeev@ronailab.net.

PMID: 26977874
DOI: 10.1016/j.ccell.2016.02.014

Abstract

The HIV1 protease inhibitor nelfinavir is being investigated as a cancer therapeutic. In this issue of Cancer Cell, Smith et al. (2016) report that nelfinavir suppresses MITF expression induced by MAPK pathway inhibition in melanoma cells and sensitizes melanoma cells with NRAS or BRAF plus NRAS mutations to MEK inhibitors.

Publication types

Comment

MeSH terms

Drug Tolerance / genetics*
Humans
Melanoma / drug therapy*
Melanoma / genetics*
Mutation / drug effects*
Mutation / genetics*
Protein Kinase Inhibitors / pharmacology*

Substances

Protein Kinase Inhibitors